Change over period: —
NSE · CIPLA
CIPLA LTD.
-7.7% from the 52-week high · +18.8% above the low
Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. The company is headquartered in Mumbai, Maharashtra and currently employs 26,615 full-time employees. The firm operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. The firm's product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The firm's geographical segments include India, the United States, South Africa, and Rest of the World. The firm has its network of manufacturing, trading and other incidental operations in India and International markets. The firm has approximately 47 manufacturing sites.
The short version. CIPLA LTD. reported revenue of ₹7,404 crore for Sep 2026, down 2.4% from a year earlier. Net profit was ₹878 crore (down 35.0% year on year). Return on equity was 11.3% in Mar 2026. Promoter holding was 29.2% in Sep 2026, up 0.01 points over 8 quarters.
1 · The price
How has the stock traded?
CIPLA LTD. trades 7.7% below its 52-week high and 18.8% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹7,404 cr.
Sep 2026 net profit of ₹878 cr.
5.9 pts lower than a year earlier.
Revenue compounded at 7.7% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7404 | 7119 | 6541 | 7074 | 7589 | 6957 | 6730 | 7073 |
| Net profit | 878 | 789 | 555 | 676 | 1351 | 1298 | 1222 | 1571 |
| Net margin % | 11.9 | 11.1 | 8.5 | 9.6 | 17.8 | 18.7 | 18.2 | 22.2 |
| EPS (₹) | 10.86 | 9.77 | 6.87 | 8.37 | 16.73 | 16.06 | 15.13 | 19.45 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 28163 | 27548 | 25774 | 22753 | 21763 | 19160 | 17132 | 16362 |
| Net profit | 3879 | 5273 | 4122 | 2802 | 2517 | 2405 | 1547 | 1528 |
| Net margin % | 13.8 | 19.1 | 16.0 | 12.3 | 11.6 | 12.6 | 9.0 | 9.3 |
| EPS (₹) | 48.02 | 65.28 | 51.05 | 34.71 | 31.19 | 29.82 | 19.18 | 18.96 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 11.3% in Mar 2026; debt to equity is 0.01.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 11.3 | 16.9 | 15.4 | 12.0 |
| Return on capital % | 14.9 | 21.6 | 21.1 | 17.0 |
| EBITDA margin % | 22.3 | 28.1 | 25.8 | 22.9 |
| Net margin % | 13.4 | 18.6 | 15.5 | 12.1 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 7.7% | 8.4% |
| Profit CAGR | 11.5% | 10.0% |
4 · The owners
Who holds it, and are they adding?
Up 0.01 pts over 8 quarters.
Down 6.4 pts over 8 quarters.
Up 7.23 pts over 8 quarters.
+72 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 29.19 | 29.2 | 29.19 | 29.22 | 29.22 | 29.22 | 29.22 | 29.2 | +0.01 |
| FII | 26.65 | 26.28 | 25.25 | 24.55 | 23.93 | 22.56 | 20.21 | 20.25 | -6.4 |
| DII | 27.71 | 28.15 | 29.26 | 30.25 | 30.72 | 31.97 | 34.63 | 34.94 | +7.23 |
| Public | 16.44 | 16.37 | 16.3 | 15.99 | 16.13 | 16.25 | 15.94 | 15.6 | -0.84 |
Mutual fund holdings · Oct 2026
344 schemes hold this stock
272 the month before.
- ICICI Prudential Nifty Pharma ETF7.67% of NAV
- Nippon India Nifty Pharma ETF7.67% of NAV
- ICICI Prudential Nifty Pharma Index Fund7.67% of NAV
- DSP Healthcare Fund7.4% of NAV
- Bandhan Healthcare Fund7.21% of NAV
- ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND7.1% of NAV
- ICICI Prudential Nifty Healthcare ETF6.73% of NAV
- DSP Nifty Healthcare ETF6.73% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for CIPLA LTD. are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about CIPLA LTD.
What is the CIPLA LTD. share price?
CIPLA LTD. (CIPLA) last closed at ₹1,418.50, up 0.11% on the day. Its 52-week range is ₹1,192.40 to ₹1,535.60.
What is the market cap of CIPLA LTD.?
CIPLA LTD. has a market capitalisation of about ₹115,190 crore.
How are CIPLA LTD.'s latest results?
CIPLA LTD. reported revenue of ₹7,404 crore for Sep 2026, down 2.4% from a year earlier. Net profit was ₹878 crore (down 35.0% year on year). Return on equity was 11.3% in Mar 2026. Promoter holding was 29.2% in Sep 2026, up 0.01 points over 8 quarters.
Who owns CIPLA LTD.?
As of Sep 2026, shareholding was: Promoter 29.2%, FII 20.25%, DII 34.94%, Public 15.6%.
How many mutual funds hold CIPLA LTD.?
344 mutual fund schemes held CIPLA LTD. in October 2026. That compares with 272 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 05 Jun 2026 · Final Dividend - Rs. 13
- 27 Jun 2025 · Special Dividend - Rs. 3
- 27 Jun 2025 · Final Dividend - Rs. 13
- 02 Aug 2024 · Final Dividend - Rs. 13
- 21 Jul 2023 · Final Dividend - Rs. 8.5
- 08 Aug 2022 · Dividend - Rs. 5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.